Evidence map›Paper›PMID 33182255›Full record

ArticleMolecules (Basel, Switzerland)2020

Discovery of 12O-A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor.

Yan Fan, Zhi Huang, Xiaoshuang Wang, Yakun Ma, Yongtao Li, Shengyong Yang, Yi Shi

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yan FanDepartment of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.ORCID 0000-0002-8099-3203
Zhi HuangDepartment of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.
Xiaoshuang WangDepartment of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.ORCID 0000-0003-1894-9444
Yakun MaDepartment of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.
Yongtao LiDepartment of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.ORCID 0000-0003-0083-2328
Shengyong YangMedical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610064, China.
Yi ShiDepartment of Medicinal Chemistry, School of Medicine, Nankai University, 94 Weijin Road, Tianjin 300071, China.
Nankai University · CNSichuan University · CN

Funding

the National Key Research and Development Program of China 2018YFE0114300the National Natural Science Foundation of China 81903099the National Natural Science Foundation of China 81972882
6 · The paper itself

Abstract

A novel series of pyrimidine-benzotriazole derivatives have been synthesized and evaluated for their anticancer activity against human solid tumor cell lines. The most promising molecule

Indexed as

Administration, OralAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationCyclin-Dependent KinasesDrug DesignDrug Screening Assays, AntitumorFemaleHeLa CellsHumansInhibitory Concentration 50MCF-7 CellsMiceMice, Inbred BALB CMice, NudeAntineoplastic AgentsCyclin-Dependent KinasesFLT1 protein, humanProtein Kinase InhibitorsPyrimidinesVascular Endothelial Growth Factor Receptor-1cancerCDKFLTinhibitor

Identifiers

PMID33182255
PMCPMC7664879
OpenAlexW3099793945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.